Why and how to step down chronic asthma drugs

Michael R. Gionfriddo, John B. Hagan, Matthew A Rank

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Asthma is a common chronic airways disease. The goal of asthma management is to control symptoms while minimizing the side effects of treatment. Following a period of stable asthma, clinicians should consider stepping down treatment. This approach is recommended by current guidelines. Step-down has been studied for several types of asthma drug regimens, and certain approaches may have lower risk than others. Systematic reviews of multiple trials support the following specific step-down approaches: optimizing inhaled corticosteroid dosing when stepping down oral corticosteroid, reducing inhaled corticosteroid from a higher dose, lowering inhaled corticosteroid-long acting bronchodilator (ICS-LABA) dose while adding ICS-LABA on-demand, adding leukotriene receptor antagonist (LTRA) while lowering inhaled corticosteroid dose, and using allergen immunotherapy when reducing inhaled corticosteroid from a higher dose. Systematic reviews of multiple trials support an increased risk of asthma exacerbation for patients who completely stop taking inhaled corticosteroid or long acting bronchodilator. Strategies to implement step-down in practice include the use of risk prediction as well as tools to support shared decision making and communication about risk between clinicians and patients.

Original languageEnglish (US)
Article numberj4438
JournalBMJ (Online)
Volume359
DOIs
StatePublished - 2017

Fingerprint

Adrenal Cortex Hormones
Asthma
Pharmaceutical Preparations
Bronchodilator Agents
Immunologic Desensitization
Leukotriene Antagonists
Decision Making
Chronic Disease
Communication
Guidelines
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Why and how to step down chronic asthma drugs. / Gionfriddo, Michael R.; Hagan, John B.; Rank, Matthew A.

In: BMJ (Online), Vol. 359, j4438, 2017.

Research output: Contribution to journalReview article

Gionfriddo, Michael R. ; Hagan, John B. ; Rank, Matthew A. / Why and how to step down chronic asthma drugs. In: BMJ (Online). 2017 ; Vol. 359.
@article{5161b7c71cd44afe9fe819540c84580c,
title = "Why and how to step down chronic asthma drugs",
abstract = "Asthma is a common chronic airways disease. The goal of asthma management is to control symptoms while minimizing the side effects of treatment. Following a period of stable asthma, clinicians should consider stepping down treatment. This approach is recommended by current guidelines. Step-down has been studied for several types of asthma drug regimens, and certain approaches may have lower risk than others. Systematic reviews of multiple trials support the following specific step-down approaches: optimizing inhaled corticosteroid dosing when stepping down oral corticosteroid, reducing inhaled corticosteroid from a higher dose, lowering inhaled corticosteroid-long acting bronchodilator (ICS-LABA) dose while adding ICS-LABA on-demand, adding leukotriene receptor antagonist (LTRA) while lowering inhaled corticosteroid dose, and using allergen immunotherapy when reducing inhaled corticosteroid from a higher dose. Systematic reviews of multiple trials support an increased risk of asthma exacerbation for patients who completely stop taking inhaled corticosteroid or long acting bronchodilator. Strategies to implement step-down in practice include the use of risk prediction as well as tools to support shared decision making and communication about risk between clinicians and patients.",
author = "Gionfriddo, {Michael R.} and Hagan, {John B.} and Rank, {Matthew A}",
year = "2017",
doi = "10.1136/bmj.j4438",
language = "English (US)",
volume = "359",
journal = "The BMJ",
issn = "0959-8146",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Why and how to step down chronic asthma drugs

AU - Gionfriddo, Michael R.

AU - Hagan, John B.

AU - Rank, Matthew A

PY - 2017

Y1 - 2017

N2 - Asthma is a common chronic airways disease. The goal of asthma management is to control symptoms while minimizing the side effects of treatment. Following a period of stable asthma, clinicians should consider stepping down treatment. This approach is recommended by current guidelines. Step-down has been studied for several types of asthma drug regimens, and certain approaches may have lower risk than others. Systematic reviews of multiple trials support the following specific step-down approaches: optimizing inhaled corticosteroid dosing when stepping down oral corticosteroid, reducing inhaled corticosteroid from a higher dose, lowering inhaled corticosteroid-long acting bronchodilator (ICS-LABA) dose while adding ICS-LABA on-demand, adding leukotriene receptor antagonist (LTRA) while lowering inhaled corticosteroid dose, and using allergen immunotherapy when reducing inhaled corticosteroid from a higher dose. Systematic reviews of multiple trials support an increased risk of asthma exacerbation for patients who completely stop taking inhaled corticosteroid or long acting bronchodilator. Strategies to implement step-down in practice include the use of risk prediction as well as tools to support shared decision making and communication about risk between clinicians and patients.

AB - Asthma is a common chronic airways disease. The goal of asthma management is to control symptoms while minimizing the side effects of treatment. Following a period of stable asthma, clinicians should consider stepping down treatment. This approach is recommended by current guidelines. Step-down has been studied for several types of asthma drug regimens, and certain approaches may have lower risk than others. Systematic reviews of multiple trials support the following specific step-down approaches: optimizing inhaled corticosteroid dosing when stepping down oral corticosteroid, reducing inhaled corticosteroid from a higher dose, lowering inhaled corticosteroid-long acting bronchodilator (ICS-LABA) dose while adding ICS-LABA on-demand, adding leukotriene receptor antagonist (LTRA) while lowering inhaled corticosteroid dose, and using allergen immunotherapy when reducing inhaled corticosteroid from a higher dose. Systematic reviews of multiple trials support an increased risk of asthma exacerbation for patients who completely stop taking inhaled corticosteroid or long acting bronchodilator. Strategies to implement step-down in practice include the use of risk prediction as well as tools to support shared decision making and communication about risk between clinicians and patients.

UR - http://www.scopus.com/inward/record.url?scp=85031724921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031724921&partnerID=8YFLogxK

U2 - 10.1136/bmj.j4438

DO - 10.1136/bmj.j4438

M3 - Review article

C2 - 29038166

AN - SCOPUS:85031724921

VL - 359

JO - The BMJ

JF - The BMJ

SN - 0959-8146

M1 - j4438

ER -